ProPharma Group
Company
ProPharma Group develops one asset, in phase 3 (Sonlicromanol in m.3243A>G-related primary mitochondrial disease). Mostly small molecule acting on Oxidative stress and ROS signalling, oxidative phosphorylation and inflammation.
- 1
- Asset
- Furthest stage
- Phase 3
- 0
- Trials
- 0
- Signals
Pipeline
1Modulates reductive and oxidative distress with anti-inflammatory properties; its active metabolite inhibits microsomal prostaglandin E synthase-1.
Phase 3, Small molecule, Oxidative stress and ROS signalling, Oxidative phosphorylation, m.3243A>G-related primary mitochondrial disease, maternally inherited diabetes and deafness, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms6
- Trials2
- Signals1
- Similar companies6